Skip to main content
Open Forum Infectious Diseases logoLink to Open Forum Infectious Diseases
. 2019 Oct 23;6(Suppl 2):S425. doi: 10.1093/ofid/ofz360.1048

1185. Impact of Utilizing Drug Resistance in Pneumonia (DRIP) Score on Management of Pneumonia

Avnish Sandhu 1, Erin Goldman 2, Jordan Polistico 1, Sarah Polistico 3, Ahmed Oudeif 2, Anil Aranha 2, Kyle P Murray 3, Jing Zhao 4, Ryan Mynatt 3, Jason M Pogue 5, Sorabh Dhar 6
PMCID: PMC6809094

Abstract

Background

Pneumonia is a leading cause of infection-related admissions and death. It is imperative that appropriate antibiotic therapy is selected. Traditional scoring systems for identifying at-risk persons for drug-resistant pathogens– i.e., Healthcare-associated pneumonia (HCAP), have been inaccurate and often lead to inappropriate antibiotic selection. A novel pneumonia scoring system –“Drug Resistance in Pneumonia (DRIP)” was implemented at the Detroit Medical Center (DMC) in January 2018. The objective of this study was to evaluate the effectiveness of the DRIP score in reducing the use of broad-spectrum antibiotics and the impact on key outcomes in patients treated for pneumonia.

Methods

A retrospective chart review of 89 patients admitted to the DMC for treatment of pneumonia was conducted—45 patients prior to and 44 patients post-implementation of the DRIP score. Basic demographics, signs and symptoms, antibiotics data, pneumonia severity score (CURB – 65), Charlson co-morbidity score, and outcome measures were compared. DRIP scores and HCAP risk factors were calculated for all patients. The definitions of broad-spectrum antibiotics (BSA) were consistent with DMC guidelines for the treatment of pneumonia (antibiotics targeting nosocomial Gram-negative organisms and/or methicillin-resistant Staphylococcus aureus).

Results

Demographics are shown in Table 1. 18 (40%) of the pre-implementation cohort had risk factors for resistance (HCAP risk factors) compared with 14 (32%) in the post. Conversely, 15 (33%) of the pre-implementation cohort had risk factors for resistance (DRIP ≥4) compared with 8 (18%) in the post-implementation period (Table 2). A difference in BSA prescribing was seen in patients previously characterized as having a high risk of resistance (HCAP) but with DRIP score <4 [5/7 (72%) vs.1/7 (16%) (Table 2)]. BSA use was 24 (53%) in the pre-implementation cohort and 12 (27%) in post-implementation cohort, P = 0.03. Durations of antibiotics were 8.3 days vs. 9.8 days respectively, P = 0.04. Readmission with pneumonia at 30 days was 3 (7.5%) for both groups.

Conclusion

The implementation of a novel DRIP scoring system resulted in improved prescribing patterns and a significant reduction of broad-spectrum antibiotics by 26% as compared with traditional HCAP score.

graphic file with name ofidis_ofz360_f0990.jpg

graphic file with name ofidis_ofz360_f0991.jpg

Disclosures

All authors: No reported disclosures.

Session: 143. HAI: Respiratory Infections (incl VAP, HAP)

Friday, October 4, 2019: 12:15 PM


Articles from Open Forum Infectious Diseases are provided here courtesy of Oxford University Press

RESOURCES